

APPENDIX 34: EXCLUDED STUDIES

STUDY ID	REASON FOR EXCLUSION
Studies of adults	
AHLFORS1981	Included participants with bipolar and unipolar depressive illness. Disaggregated data was not available
AHUJA2011	Results not available
ALTAMURA2003	Comparison not eligible
ALTAMURA2004	Maintenance trial with a follow-up of less than 1 year
AMSTERDAM2005b	Maintenance trial with a follow-up of less than 1 year
AMSTERDAM2008	Open label
AMSTERDAM2009	Open label
AMSTERDAM2010	Maintenance trial with a follow-up of less than 1 year
ASTRAZENECA2012a	Open label
ASTRAZENECA2012b	Open label
BAASTRUP1970	Included participants until the result was statistically significant. Participants did not give consent and some were not aware that their lithium tablets had been exchanged for placebo. Only 60% had bipolar disorder and disaggregated data was not available
BENEDETTI1997	Only five participants in each group
BERK2008	Drug not indicated for mental health and not in common use
BERK2012	Drug not indicated for mental health and not in common use
BOSE2012	Results not available
BOWDEN2010	Maintenance trial with a follow-up of less than 1 year
BOWDEN2012	Maintenance trial with a follow-up of less than 1 year
BURDICK2012	Maintenance trial with a follow-up of less than 1 year
CALABRESE2000	Maintenance trial with a follow-up of less than 1 year
CAMURI2013	No sham control group
CHENGAPPA2000	Drug not indicated for mental health and not in common use
COHN1989	Dose outside range in the British National Formulary
COLOMBO2000	Only efficacy outcomes are mood visual analogue scales with no suggestion of validity
COSTA2011	The allocation of participants was not random
CUNDALL1972	Maintenance trial with a follow-up of less than 1 year
DASHTBOZORGI2009	Trial of family psychoeducation in Iran. The Guideline Development Group agreed this was not relevant to the UK
DENICOFF2005	Drug not indicated for mental health and not in common use
DIAZGRANDOS2010	Drug not indicated for mental health and not in common use
DOLBERG2002	No sham control group
ELMALLAKH2009	Maintenance trial with a follow-up of less than 1 year
ESPARON1986	Drug not indicated for mental health and not in common use
FIEVE1968	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
FOREST2010	Data was not provided
FOREST2012	Results not available
FRANGOU2006	Does not meet inclusion criteria for acute depression

STUDY ID	REASON FOR EXCLUSION
FURLEY2013	Drug not indicated for mental health and not in common use
GAO2008	Authors did not provide data
GINDRE2009	Protocol of a trial; authors have not confirmed whether trial has been completed
GOLDBERG2004	Did not include a sufficient number of participants
GRISARU1998	No sham control group
GSK2012	Maintenance trial with a follow-up of less than 1 year
HIMMELHOCH1991	Did not report response on an accepted measure
JACKSON2008	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
KAFANTARIS2004	Participants were not acutely manic at baseline
KECK2006a	Maintenance trial with a follow-up of less than 1 year
KESSELL1975	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
KULKARNI2006	Drug not indicated for mental health and not in common use
MARANGELL2006	Only ten participants in total
MCELROY2011	Drug not indicated for mental health and not in common use
MCELROY2013	Results not available
MURPHY2012	Maintenance trial with a follow-up of less than 1 year
NIERENBERG2006	Open label
NIERENBERG2013	Maintenance trial with a follow-up of less than 1 year
NOLEN2007	Open label
NORRIS2013	Drug not indicated for mental health and not in common use
OKUMA1981	Results not available
OSHER2005	Only 6 participants in each group
PICKETT-SCHENK2008	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
PRAHARAJ2009	The allocation of participants was quasi-random
PRASKO2013	On-going trial
SACHS2007	No relevant network
SCHAFFER2013	Open label
SHEEHAN2009	Treatment of 'bipolar anxiety'
SHEEHAN2013	Treatment of 'bipolar anxiety'
SINGH2013	Open label
SMITH1978	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
SOLOMON1997	Only 12 participants in total
SPEER2009	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
STAMM2011	Drug not indicated for mental health and not in common use
STARING2010	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
STOLL1999	Maintenance trial with a follow-up of less than 1 year
SUPPES1999	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available
SZUBA2005	Drug not indicated for mental health and not in common use
TAMAYO2009	Open label

Excluded studies

STUDY ID	REASON FOR EXCLUSION
TOHEN2006	Maintenance trial with a follow-up of less than 1 year
VITA2013	Open label
WANG2010	Open label
WATSON2012	Drug not indicated for mental health and not in common use
WOO2011	Maintenance trial with a follow-up of less than 1 year
YANG2009	Full report not available
YONGNING2005	Open label
YOUNG2000	Did not include a sufficient number of participants
YOUNG2004	Drug not indicated for mental health and not in common use
ZARATE2004	Maintenance trial with a follow-up of less than 1 year
ZARATE2004b	Less than ten participants per group
ZARATE2012	No relevant network
ZHANG2007	Drug not indicated for mental health and not in common use
Studies of children	
FINDLING2013	Maintenance trial with a follow-up of less than 1 year
GELLER2012	Open label
JOSHI2013	Open label
KOWATCH2000	Open label
WOZINAK2012	Study terminated
WOZNIAK2009	The allocation of participants was quasi-random

Excluded case identification studies

STUDY ID	REASON FOR EXCLUSION
BENZAZZI2003	No healthy controls (clinical sample of remitted patients with bipolar and major depressive disorder)
CASTELO2012	No structured clinical interview done; validation against primary care medical records
CHUNG2009	Instrument not in English (Chinese version of Mood Disorder Questionnaire)
DAS2005	No structured clinical interview done; validation against primary care medical records
DESOUSAGURGEL2012	Instrument not in English (Portuguese version of Mood Disorder Questionnaire); sample was clinical and university students
FREEMAN2012	No healthy controls (sample from academic medical centre enriched for mood disorders and community mental health centre)
FREY2012	Sample consisted only of pre- and post-partum women referred with psychiatric problems
GRAVES2007	Sample consisted only of participants subject to trauma, not generalisable to general population
HIRSCHFELD2005	Not comparable to general population; patients treated for depression attending primary care, high scorers
JON2009	Instrument not in English (Korean version of Mood Disorder Questionnaire); no structured clinical interview
KEMP2008	Not comparable to general population; adult detainees in a prison only

STUDY ID	REASON FOR EXCLUSION
MEYER2011	No healthy controls (clinical sample of patients from psychiatric clinics an outpatient clinics)
MILLER2011	Three studies: study 1 did not use structured clinical interview; study 2 - participants were not administered Hypomanic Personality Scale-6 as a screening instrument; study 3 - not comparable with general population as only university students and high scorers
PRETI2007	Not specific for bipolar; we wrote to the author to ask for results in bipolar subgroup but those were not available
SANCHEZMORENO2008	Instrument not in English (Spanish version of Mood Disorder Questionnaire); no structured clinical interview
VIETA2007	Instrument not in English (Spanish version of Mood Disorder Questionnaire); participants attended clinics (not clear where the healthy controls were selected from); no structured clinical interview
YOUNG1978	No healthy controls (participants were adult patients admitted to hospital with mania)
YOUNGSTROM2011	Conference abstract; no full text available; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
YOUNGSTROM2004	Not comparable to general population; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
YOUNGSTROM2003	Not comparable to general population; clinical sample (participants recruited from research patients seen at a division of child and adolescent psychiatry)
YOUNGSTROM2005	Not comparable to general population; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
ZIMMERMAN2010	Reports four studies that use a clinical sample (psychiatric outpatients): Hardoy and colleagues (2005), Konuk and colleagues (2007), Zimmerman and colleagues (2009) and Benazzi (2003)

Studies that were ongoing or awaiting assessment

STUDY ID	REASON FOR EXCLUSION
AHUJA2011	Results not available
BOSE2012	Results not available
BRISTOLMYERSSQUIBB2011	Results not available
FOREST2010	Results not available
FOREST2012	Results not available
FRYE2000	Results not available
GAO2008	Authors did not provide data
GINDRE2009	Protocol of a trial; authors have not confirmed whether trial has been completed
KNESEVICH2009	Results not available
MCELROY2013	Results not available
OKUMA1981	Results not available
PRASKO2013	On-going trial
YANG2009	Full report not available

References

Ahlfors UG, Baastrup PC. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. *Acta Psychiatrica Scandinavica*. 1962;64:226-37.

Ahuja S, Bose A, Lu K, Greenberg W, Németh G, Laszlovszky I. A Multicenter, Randomized, double-blind trial to evaluate the effect of cariprazine in bipolar depression. Conference of the International Society for CNS Clinical Trials and Methodology, 3-4 October 2011, Amelia Island, Florida, US.

Altamura AC, Russo M, Vismara S, Mundo E. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. *Journal of Clinical Psychopharmacology*. 2004;24:454-6.

Altamura AC, Salvadori D, Madaro D, Santini A, Mundo E. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. *Journal of Affective Disorders*. 2003;76:267-71.

Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with bipolar II major depressive episode? *Journal of Affective Disorders*. 2009;115:234-40.

Amsterdam JD, Luo L, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. *American Journal of Psychiatry*. 2010;167:792-800.

Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. *International Clinical Psychopharmacology*. 2005;20:257-64.

AstraZeneca. Effectiveness of quetiapine XR vs. sertraline in acute bipolar depression as add-on therapy to previous mood stabilizer treatment: a pilot study. NCT00857584/D1443L00058. (Unpublished); 2012a. Available from: <http://clinicaltrials.gov/show/NCT00857584>

AstraZeneca. Efficacy and safety of quetiapine vs. quetiapine plus lithium in bipolar depression (QUALITY). NCT00883493/D1443L00055. (Unpublished); 2012b. Available from: <http://clinicaltrials.gov/show/NCT00883493>

Baastrop PC, Poulsen JC, Schou M, Thomsen K, Amidsen A. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. *Lancet*. 1970;2:326-30.

Benazzi F. Improving the Mood Disorder Questionnaire to detect bipolar II disorder. *Canadian Journal of Psychiatry*. 2003;48:770-01.

Benedetti F, Barbini B, Lucca A, Campori E, Colombo C, Smeraldi E. Sleep deprivation hastens the antidepressant action of fluoxetine. *European Archives of Psychiatry and Clinical Neuroscience*. 1997;247:100-03.

Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. *BMC Medicine*. 2012;10:91.

Berk MC, Copolov SI, Dean O, Lu K, Jeavons S, Schapkaitz, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. *Biological Psychiatry*. 2008;64:468-75.

Bose A, Starace A, Wang Q, Diaz E, Goodman J, Ruth A, et al. Cariprazine in the treatment of acute mania in bipolar disorder: A double-blind, placebo-controlled, phase III trial. 165th Annual Meeting of the American Psychiatric Association, 5-9 May 2012, Philadelphia, USA.

Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. *Journal of Clinical Psychiatry*. 2010;71:130-7.

Bowden CL, Singh V, Weisler R, Thompson P, Chang X, Quinones M, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. *Acta Psychiatrica Scandinavica*. 2012;126:342-50.

Bristol-Myers Squibb. A 12-week, multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of adjunctive aripiprazole therapy in the treatment of mania in bipolar I disorder patients treated with valproate or lithium and in need of further clinical improvement. (Unpublished); 2011. Available from: <http://clinicaltrials.gov/ct2/show/NCT00665366>

Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. *Journal of Clinical Psychiatry*. 2012;73:103-12.

Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. *Journal of Clinical Psychiatry*. 2000;61:841-50.

Camuri G, Dell'Osso B, Guerrieri I, Arici C, Oldani L, Altamura AC. Augmentative repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of drug-resistant depression. Abstracts of the 21th European Congress of Psychiatry, 6-9 April 2013, Nice, France. *European Psychiatry*. 2013;28:S1.

Castelo MS, Hyphantis TN, Macêdo DS, Lemos GO, Machado YO, Kapczinski F, et al. Screening for bipolar disorder in the primary care: a Brazilian survey. *Journal of Affective Disorders*. 2012;143:118-24.

Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A et al. Inositol as an add-on treatment for bipolar depression. *Bipolar Disorders*. 2000;2:47-55.

Chung KF, Tso KC, Chung RT. Validation of the Mood Disorder Questionnaire in the general population in Hong Kong. *Comprehensive Psychiatry*. 2009;50:471-6.

Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: Replication of main effects and interaction. *Psychiatry Research*. 2000;95:43-53.

Costa RT, Cheniaux E, Rosaes PA, Carvalho MR, Freire RC, Versiani M, et al. The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study. *Revista Brasileira de Psiquiatria*. 2011;33:144-9.

Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. *Psychological Medicine*. 1972;2:308-11.

Das AK, Olfson M, Gameroff MJ, Pilowsky DJ, Blanco C, Feder A, et al. Screening for bipolar disorder in a primary care practice. *JAMA: The Journal of the American Medical Association*. 2005;293:956-63.

Dashtbozorgi B, Ghadirian F, Khajeddin N, Karam K. Effect of family psychoeducation on the level of adaptation and improvement of patients with mood disorders. *Iranian Journal of Psychiatry and Clinical Psychology*. 2009;15:193-200.

de Sousa Gurgel W, Rebouças DB, Negreiros de Matos KJ, Carneiro AH, Gomes de Matos e Souza F, Affective Disorders Study Group. Brazilian Portuguese validation of Mood Disorder Questionnaire. *Comprehensive Psychiatry*. 2012;53:308-312.

Denicoff KD, Singh J, Sporn J, Zarate CA, Quiroz JA, Brutsche NE, et al. Antiglucocorticoid therapy in bipolar depression with mifepristone. *Bipolar Disorders*. 2005;7:47.

Diazgranados N, Ibrahim L, Brutsche N, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. *Archives of General Psychiatry*. 2010;67:793-802.

Dolberg O, Dannon PN, Schreiber S, Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: A double blind, controlled study. *Bipolar Disorders*. 2002;4:94-5.

El-Mallakh RS, Salem MR, Chopra AS, Mickus GJ, Penagaluri P. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study. *International Clinical Psychopharmacology*. 2009;24:145-9.

Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. *British Journal of Psychiatry*. 1986;148:723-5.

Fieve, RR, Platman SR, Plutchik RH. The use of lithium in affective disorders. I. Acute endogenous depression. *The American Journal of Psychiatry*. 1968;125:487-91

Findling RLK, Kafantaris V, Pavuluri M, McNamara NK, Frazier JA, Sikich L, et al. Post-acute effectiveness of lithium in pediatric bipolar I disorder. *Journal of Child and Adolescent Psychopharmacology*. 2013;23:80-90.

Forest Laboratories. Forest Laboratories, Inc. and Gedeon Richter Plc announce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder. 2012. Available from: <http://news.frx.com/press-release/product-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-ii>

Forest Laboratories. Forest Laboratories, Inc. and Gedeon Richter Plc announce results from a phase II study of cariprazine for the treatment of bipolar depression.

2010. Available from: <http://news.frx.com/press-release/rd-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-phase-ii-stu-0>

Frangou SL, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. *British Journal of Psychiatry*. 2006;188:46-50.

Freeman AJ, Youngstrom EA, Frazier TW, Youngstrom JK, Demeter C, Findling RL. Portability of a screener for pediatric bipolar disorder to a diverse setting. *Psychological Assessment*. 2012;24:341-51.

Frey BN, Simpson W, Wright L, Steiner M. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. *Journal of Clinical Psychiatry*. 2012;73:1456-61.

Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. *Journal of Clinical Psychopharmacology*. 2000;20:607-14.

Furey ML, Zarate CA. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side. *Journal of Clinical Psychiatry*. 2013;74:850-1.

Gao K, Kemp DE, Ganocy SJ, Muzina DJ, Xia G, Findling RL. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. *Bipolar Disorders*. 2008;10:907-15.

Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. *Archives of General Psychiatry*. 2012;69:515-28.

Gindre CH, Husky M, Brebant C, Gay C, Cuche H, Swendsen J. Changes in daily life associated with psychoeducation for bipolar disorder. *Annales Medico-Psychologiques*. 2009;167:280-4.

GlaxoSmithKline. An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in patients with bipolar I disorder [SCA104779]. (Unpublished); 2012. Available from: <http://www.gsk-clinicalstudyregister.com/study/SCA104779#ps>

Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. *American Journal of Psychiatry*. 2004;161:564-6.

Graves RE, Alim TN, Aigbogun N, Chrishon K, Mellman TA, Charney DS. Diagnosing bipolar disorder in trauma exposed primary care patients. *Bipolar Disorders*. 2007;9:318-23.

Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH. Transcranial magnetic stimulation in mania: a controlled study. *American Journal of Psychiatry*. 1998;155:1608-10.

Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. *American Journal of Psychiatry*. 1991;148:910-16.

Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. *The Journal of the American Board of Family Practice*. 2005;18:233-9.

Jackson HG, McGorry PD, Killackey E, Bendall S, Allott K, Dudgeon P, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. *Psychological Medicine*. 2008;38:725-35.

Jon DI, Hong N, Yoon BH, Jung HY, Ha K, Shin YC, et al. Validity and reliability of the Korean version of the Mood Disorder Questionnaire. *Comprehensive Psychiatry*. 2009;50:286-91.

Joshi G, Petty C, Wozniak J, Faraone SV, Spencer AE, Woodworth KY. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. *Psychopharmacology*. 2013;227:449-58.

Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir J, et al. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2004;43:984-93.

Keck Jr PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. *Journal of Clinical Psychiatry*. 2006;67:626-37.

Kemp DE, Hirschfeld RM, Ganocy SJ, Elhaj O, Slembariski R, Bilali S, et al. Screening for bipolar disorder in a county jail at the time of criminal arrest. *Journal of Psychiatric Research*. 2008;42:778-86.

Kessell A, Holt NF. A controlled study of a tetracyclic antidepressant - maprotiline (Ludiomil). *Medical Journal of Australia*. 1975;1:773-6.

Knesevich M, Wang Q, Bose A, Papadakis K, Starace A, Thomson L, Andor Gy, Németh G, Laszlovszky I. Phase II trial cariprazine in acute mania associated with bipolar I disorder: effect across symptoms. 49th Annual New Research Approaches for Mental Health Interventions Meeting, 29 June -2 July, Hollywood, FL; 2009.

Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*. 2000;39:713-20.

Kulkarni JG. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. *Psychoneuroendocrinology*. 2006;31:543-7.

McElroy S. Short-and longer-term treatment with lurasidone in patients with bipolar I depression: Effect on metabolic syndrome. *Neuropsychopharmacology*. 2013;38:S535-S536.

McElroy SLW. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. *International Clinical Psychopharmacology*. 2011;26:48-53.

Meyer TD, Bernhard B, Born C, Fuhr K, Gerber S, Schaerer L, et al. The Hypomania Checklist-32 and the Mood Disorder Questionnaire as screening tools - going beyond samples of purely mood-disordered patients. *Journal of Affective Disorders*. 2011;128:291-8.

Miklowitz DJ, Schneck CD, Singh MK, Taylor DO, George EL, Cosgrove VE, et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2013;52:121-31.

Miller CJ, Johnson SL, Kwapil TR, Carver CS. Three studies on self-report scales to detect bipolar disorder. *Journal of Affective Disorders*. 2011;128:199-210.

Murphy BL, Stoll AL, Harris PQ, Ravichandran C, Babb SM, Carlezon WA Jr et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: A double-blind, randomized add-on clinical trial. *Journal of Clinical Psychopharmacology*. 2012;32:699-703.

Nierenberg AA, Friedman ES, Bowden CL, Sylvia LG, Thase ME, Ketter T, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. *The American Journal of Psychiatry*. 2013;170:102-10.

Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, et al. Treatment resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol or risperidone. *American Journal of Psychiatry*. 2006;163:210-6.

Nolen WA, Kupka RW, Helleman G, Frye MA, Altshuler LL, Leverich GS, et al. Tranylcypramine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study. *Acta Psychiatrica Scandinavica*. 2007;115:360-5.

Norris ER, Karen B, Correll JR, Zemanek KJ, Lerman J, Primelo RA, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. *Journal of Affective Disorders*. 2013;144:141-7.

Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. *Psychopharmacology*. 1981;73: 95-6

Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. *Journal of Clinical Psychiatry*. 2005;66:726-9.

Pickett-Schenk SA, Lippincott RC, Bennett C, Steigman PJ. Improving knowledge about mental illness through family-led education: the journey of hope. *Psychiatric Services*. 2008;59:49-56.

Praharaj SK, Ram D, Arora M. Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study. *Journal of Affective Disorders*. 2009;117:146-150.

Prasko J, Latalova K, Cerna M, Grambal A, Jelenova D, Kamaradova D, et al. Internet based psychoeducative CBT program for bipolar patients treated with thymostabilisers. Abstracts of the 21st European Congress of Psychiatry, 6-9 April 2013, Nice, France. *European Psychiatry*. 2013;28.

Preti A, Rocchi MB, Sisti D, Mura T, Manca S, Siddi S, et al. The psychometric discriminative properties of the Peters et al Delusions Inventory: a receiver operating characteristic curve analysis. *Comprehensive Psychiatry*. 2007;48:62-9.

Sanchez-Moreno J, Villagran JM, Gutierrez JR, Camacho M, Ocio S, Palao D, et al. Adaptation and validation of the Spanish version of the Mood Disorder Questionnaire for the detection of bipolar disorder. *Bipolar Disorders*. 2008;10:400-12.

Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. *New England Journal of Medicine*. 2007;356:1711-22.

Schaffer LC, Schaffer CB, Miller AR, Manley JL, Piekut JA, Nordahl TE. An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. *Journal of Affective Disorders*. 2013;147:407-10.

Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr, Janavs J, Rogers J, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. *Journal of Affective Disorders*. 2009;115:376-85.

Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. *Journal of Affective Disorders*. 2013;145:83-94.

Singh V, Bowden CL, Mintz J. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. *International Clinical Psychopharmacology*. 2013;28:91-5.

Smith AH, Naylor GS, Moody JP. Placebo-controlled double-blind trial of mianserin hydrochloride. *British Journal of Clinical Pharmacology*. 1978;5:67S-70S.

Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. *Journal of Clinical Psychiatry*. 1997;58:95-9.

Speer AM, Benson BE, Kimbrell TK, Wassermann EM, Willis MW, Herscovitch P, et al. Opposite effects of high and low frequency rTMS on mood in depressed patients: Relationship to baseline cerebral activity on PET. *Journal of Affective Disorders*. 2009;115:386-94.

Stamm TA, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, et al. Supraphysiological doses of levothyroxine in bipolar depression: A randomised controlled, double blind study. *Journal of Clinical Psychiatry*. 2014;75:162-8.

Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. *British Journal of Psychiatry*. 2010;197:448-55.

Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega-3 Fatty Acids in Bipolar Disorder. *Archives of General Psychiatry* 1999;56:407-12.

- Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomised 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. *American Journal of Psychiatry*. 1999;156:1164-9.
- Szuba MP, Amsterdam JD, Fernando AT 3rd, Gary KA, Whybrow PC, Winokur A. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. *Journal of Clinical Psychopharmacology*. 2005;25:325-30.
- Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. *Journal of Clinical Psychopharmacology*. 2009;29:358-61.
- Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. *American Journal of Psychiatry*. 2006;163(2):247-56.
- Vieta, E, Sánchez-Moreno J, Bulbena A, Chamorro L, Ramos JL, Artal J, et al. Cross validation with the mood disorder questionnaire (MDQ) of an instrument for the detection of hypomania in Spanish: the 32 item hypomania symptom check list (HCL-32). *Journal of Affective Disorders*. 2007;101:43-55.
- Vita A, De Peri L, Siracusano A, Sacchetti E. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: Meta-analyses of randomized-controlled trials. *International Clinical Psychopharmacology*. 2013;28:219-27.
- Wang Z, Gao K, Kemp DE, Chan PK, Serrano MB, Conroy C, et al. Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. *Psychopharmacology Bulletin*. 2010;43:5-21.
- Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. *Biological Psychiatry*. 2012;72:943-9.
- Woo YSB, Bahk WM, Chung MY, Kim DH, Yoon BH, Lee JH, et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. *Human Psychopharmacology*. 2011;26:543-53.
- Wozniak JM. Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents. NCT00592683.

(Unpublished); 2012. Available from:
<http://clinicaltrials.gov/ct2/show/NCT00592683>

Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. *Journal of Child and Adolescent Psychopharmacology*. 2009;19:539-45.

Yang FD, Li J, Tan YL, Chen DC, Yao FX, Zhang XL, et al. Optimized therapeutic scheme and individualized dosage of sodium valproate in patients with bipolar disorder sub-type I. *Chinese Journal of New Drugs*. 2009;18:47-52.

Yong Ning Z, Z Hui. Therapeutic Effect of Mirtazapine Combined with Lithium Carbonate on Bipolar Depression. *Chinese Mental Health Journal*. 2005;19:492-4.

Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. *American Journal of Psychiatry*. 2000;157:124-6.

Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. *Neuropsychopharmacology*. 2004;29:1538-45.

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry*. 1978;133:429-35.

Youngstrom EA, Gracious BL, Danielson CK, Findling RL, Calabrese J. Toward an integration of parent and clinician report on the Young Mania Rating Scale. *Journal of Affective Disorders*. 2003;77:179-90.

Youngstrom EA, Findling RL, Calabrese JR, Gracious BL, Demeter C, Bedoya DD, et al. Comparing the diagnostic accuracy of six potential screening instruments for bipolar disorder in youths aged 5 to 17 years. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2004;43:847-58.

Youngstrom EA, Meyers O, Demeter C, Youngstrom J, Morello L, Piiparinen R, et al. Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. *Bipolar Disorders*. 2005;7:507-17.

Youngstrom EA, Van Meter A, Algorta GP, Marcinick H, Freeman A, Meyers O, et al. Can we detect bipolar in youths? Diagnostic efficiency of caregiver, youth, and teacher report of manic symptoms in outpatient settings. *Neuropsychopharmacology*. 2011;36:S420-S421.

Zarate Jr CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. *American Journal of Psychiatry*. 2004;161:169-71.

Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. *Journal of Psychiatric Research*. 2007;41:360-9.

Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. *Biological Psychiatry*. 2004;56:54-60.

Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biological Psychiatry*. 2012;71:939-46.

Zimmerman M, Ruggero CJ, Galione JN, McGlinchey JB, Dalrymple K, Chelminski I, et al. Detecting differences in diagnostic assessment of bipolar disorder. *Journal of Nervous and Mental Disease*. 2010;198:339-42.